Therapies to Decrease Severe Respiratory Syncytial Virus Illness

Elizabeth A Scruggs-Wodkowski; Preeti N Malani; Kathleen A Linder

doi:10.1001/jama.2024.7406

Therapies to Decrease Severe Respiratory Syncytial Virus Illness

JAMA. 2024 Jun 25;331(24):2127-2128. doi: 10.1001/jama.2024.7406.

Authors

Elizabeth A Scruggs-Wodkowski^{1

2}, Preeti N Malani^{2

3}, Kathleen A Linder^{1

2}

Affiliations

¹ Infectious Diseases Section, Ann Arbor VA Healthcare System, Ann Arbor, Michigan.
² Department of Internal Medicine, Michigan Medicine, Ann Arbor.
³ Deputy Editor, JAMA.

PMID: 38814625
DOI: 10.1001/jama.2024.7406

No abstract available

Plain language summary

This JAMA Insights discusses the use of monoclonal antibodies or protein-based vaccines to help prevent severe RSV infection in infants, children, and older adults.

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / therapeutic use
Antiviral Agents* / therapeutic use
Child
Child, Preschool
Female
Humans
Infant
Infant, Newborn
Palivizumab / therapeutic use
Pregnancy
Respiratory Syncytial Virus Infections* / drug therapy
Respiratory Syncytial Virus Infections* / prevention & control
Respiratory Syncytial Virus Vaccines* / therapeutic use

Substances

Antiviral Agents
Palivizumab
nirsevimab
Antibodies, Monoclonal, Humanized
Respiratory Syncytial Virus Vaccines